ArticleJournal of the American Heart Association2020
Postimplant Phosphodiesterase Type 5 Inhibitors Use Is Associated With Lower Rates of Thrombotic Events After Left Ventricular Assist Device Implantation.
Article in Journal of the American Heart Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Long-term effects of phosphodiesterase-5 inhibitors on cardiovascular outcomes and death: a systematic review and meta-analysis.European heart journal. Cardiovascular pharmacotherapy · 2024Pooled it
- Effect of sildenafil on platelet activation and mediators of vascular remodelling during LVAD support.ESC heart failure · 2026Trial
- Beyond pulmonary arterial hypertension: sotatercept across the advanced heart failure and transplant continuum.Frontiers in transplantation · 2026Article
- Pharmacological management of major complications following left ventricular assist device implantation in type 2 diabetes mellitus.World journal of diabetes · 2025Review
- Article
- Phosphodiesterase-5 inhibitors for left ventricular assist device implantation complicated by right ventricular failure.ESC heart failure · 2023Article
- Review
- Neurologic Complications in Patients With Left Ventricular Assist Devices.The Canadian journal of cardiology · 2023Review
- Post-Implant Phosphodiesterase-5 Inhibitors in Patients with Left Ventricular Assist Device: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2022Review
- Management of Pulmonary Hypertension in Patients on Left Ventricular Assist Device Support.Reviews in cardiovascular medicine · 2022Review
- Outcomes With Phosphodiesterase-5 Inhibitor Use After Left Ventricular Assist Device: An STS-INTERMACS Analysis.Circulation. Heart failure · 2022Article
- Twelfth Interagency Registry for Mechanically Assisted Circulatory Support Report: Readmissions After Left Ventricular Assist Device.The Annals of thoracic surgery · 2022Article
- Stroke epidemiology and outcomes in the modern era of left ventricular assist devices.Heart failure reviews · 2022Review
- Case report: incessant ventricular fibrillation in a conscious left ventricular assist device patient.European heart journal. Case reports · 2021Article
- Phosphodiesterase type 5 inhibitors after left ventricular assist device: no free lunch?ESC heart failure · 2021Article
- Increased bleeding risk with phosphodiesterase-5 inhibitors after left ventricular assist device implantation.ESC heart failure · 2021Article
- Postimplant Phosphodiesterase Type 5 Inhibitors Use Is Associated With Lower Rates of Thrombotic Events After Left Ventricular Assist Device Implantation.Journal of the American Heart Association · 2020Article
- Phosphodiesterase-5 Inhibitor Therapy for Left Ventricular Assist Device Patients: More Data, More Questions.Journal of the American Heart Association · 2020Article
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Left ventricular assist device (LVAD) thrombosis is clinically devastating and impacts the cost effectiveness of LVAD therapy for advanced heart failure. Anticoagulation and antiplatelet therapies represent the standard of care to mitigate LVAD thrombosis. Phosphodiesterase type 5 inhibitors (PDE-5is) exhibit hemodynamic, antiplatelet, and antithrombotic effects. Using a national registry, we examined the relationship of PDE-5i use on thrombotic events in patients with continuous-flow LVADs. Methods and Results We obtained data from 13 772 patients with continuous flow LVADs participating in a national registry. Patients implanted with primary LVADs from 2012 to 2017 were included in the analysis. The primary end point was a composite of LVAD thrombosis and ischemic stroke. Patients were analyzed according to any use of PDE-5i after LVAD implantation (PDE-5i group) versus no use after LVAD implantation (no PDE-5i group). The primary end point was significantly lower in the PDE-5i group compared with the no PDE-5i group (hazard ratio [HR], 0.84; 95% CI, 0.77-0.91;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.